Iron accumulation triggered oxidative stress, inflammation, and cell death.
For the 200 million people worldwide whose central vision is quietly being consumed by age-related macular degeneration, science has long struggled to name a cause worthy of the damage. Researchers in Paris have now identified iron dysregulation—not merely as a bystander, but as an active architect of retinal destruction—and found that a protein the body already makes, transferrin, can restore balance and protect the cells that make sight possible. The discovery, born from collaboration between Inserm, Cochin Hospital, and biotech firm PulseSight Therapeutics, reframes dry AMD as a disease with a mechanistic root, and with that reframing comes the possibility of a genuine remedy.
- Iron accumulation in aging eyes triggers a cascade of oxidative stress, inflammation, and ferroptosis—a form of programmed cell death—that quietly dismantles the retina before patients notice the loss.
- Dry AMD steals the most intimate visual tasks first: reading a page, recognizing a face, finding one's way through a room—and its most severe form, geographic atrophy, leaves irreversible blind patches with no approved cure.
- Laboratory experiments showed that flooding human retinal cells with excess iron reproduced the hallmarks of AMD pathology, while adding transferrin significantly reversed the damage—offering researchers a mechanistically grounded target for the first time.
- PulseSight's PST-611 gene therapy proposes to turn the eye's own ciliary muscle cells into transferrin-producing factories, delivering the iron-regulating protein directly where it is needed through a minimally invasive electro-transfection system.
- Phase I trials are underway in France with results expected by early 2026, positioning PST-611 as a potential entrant into a dry AMD market projected to reach $27.5 billion by 2031—and a rare source of hope for patients who currently have almost none.
A research team working across Paris hospitals has published peer-reviewed evidence that iron accumulation in the eye is a primary driver of dry age-related macular degeneration—the leading cause of central vision loss in older adults worldwide. The finding offers something the field has long lacked: a mechanistic explanation for why the disease progresses, and a credible target for stopping it.
Dry AMD affects roughly 200 million people globally, advancing slowly and stealing the vision needed for reading, recognizing faces, and navigating daily life. In its most severe form, geographic atrophy, patches of the retina deteriorate beyond recovery. Effective treatments have remained scarce, and the underlying biology has been poorly understood—until now.
The study, conducted by scientists at Inserm and Cochin Hospital in collaboration with PulseSight Therapeutics, examined eye fluid from dry AMD patients and found elevated iron levels compared to healthy controls. When human retinal cells were exposed to excess iron in the laboratory, the results were striking: oxidative stress, inflammation, mitochondrial damage, and ferroptosis—a form of cell death—all emerged. These are the precise hallmarks of AMD pathology. When transferrin, an iron-regulating protein naturally produced by the body, was introduced, the damage was significantly reduced and cellular integrity was restored.
PulseSight is translating this mechanism into a therapy. Their candidate, PST-611, uses a non-viral gene delivery system to introduce transferrin-encoding genetic material directly into the eye, repurposing ciliary muscle cells as biological producers of the protective protein. The approach requires retreatment only every four to six months. Phase I trials launched in France in 2025, with results anticipated by early 2026.
For patients facing the slow, irreversible erosion of their central vision, the prospect of a treatment that addresses iron dysregulation at its source—rather than managing symptoms downstream—marks a meaningful shift in how this ancient and common disease might finally be confronted.
A team of researchers working across Paris hospitals has found evidence that iron accumulation in the eye may be a primary driver of dry age-related macular degeneration, the leading cause of vision loss in older adults worldwide. The discovery, published this week in a peer-reviewed journal, offers a mechanistic explanation for why the disease progresses and points toward a potential treatment: restoring the eye's ability to regulate iron through a protein called transferrin.
Dry AMD affects roughly 200 million people globally and unfolds gradually, stealing central vision in ways that make reading, recognizing faces, and navigating the world increasingly difficult. The disease can advance into a more severe stage called geographic atrophy, where patches of the retina deteriorate irreversibly. Until now, the underlying biology has remained murky—AMD is complex, and effective treatments remain scarce. But the new research, conducted by scientists at Inserm and Cochin Hospital in collaboration with PulseSight Therapeutics, a biotech company developing eye therapies, suggests that iron dysregulation may be the culprit.
The study examined fluid samples from the eyes of dry AMD patients and compared them to healthy controls. The researchers found elevated iron levels and signs of iron overload in the AMD patients. They then conducted laboratory experiments using human retinal cells, exposing them to excess iron. The results were striking: iron accumulation triggered oxidative stress, inflammation, damage to the cells' energy-producing structures, and a form of cell death called ferroptosis—all hallmarks of AMD pathology. When the team added transferrin, an iron-regulating protein naturally present in the body, the damage was significantly reduced. The cells recovered their structural integrity and the inflammatory cascade was dampened.
Transferrin works by binding iron and transporting it in a non-toxic form, preventing the harmful buildup that drives cellular damage. The protein is endogenous—already made by the body—which suggests it could be a safe therapeutic target. The research validates what some vision scientists have suspected for years: that iron is not merely a bystander in AMD but an active driver of the disease, particularly in its early stages.
PulseSight is betting on this mechanism. The company is developing PST-611, a gene therapy that delivers a plasmid encoding human transferrin directly into the eye using a minimally invasive electro-transfection system. The approach is designed to turn ciliary muscle cells into biological factories that produce transferrin, allowing the protein to reach the retina and restore iron balance. The therapy entered Phase I clinical trials in France in 2025, with results expected by early 2026. If successful, it would require retreatment only every four to six months—a significant advantage over more frequent dosing schedules.
The dry AMD market is substantial and growing. Estimates suggest it could reach $27.5 billion by 2031, reflecting both the scale of the disease and the desperation for better options. Joshua Dunaief, a University of Pennsylvania researcher and pioneer in studying iron's role in retinal disease, called the new findings "very enthusiastic" evidence that iron modulation deserves serious clinical attention. Thierry Bordet, PulseSight's chief scientific officer, emphasized that the company's approach combines mechanistic relevance—it targets a root cause—with a delivery platform already validated for safety and durability. For patients facing the slow, irreversible loss of their central vision, the possibility of a treatment that addresses iron dysregulation at its source represents a meaningful shift in how the disease might be approached.
Notable Quotes
Iron can promote oxidative damage and inflammation, both of which are central in disease progression. I am very enthusiastic to see programs such as PST-611 entering clinic.— Joshua Dunaief, University of Pennsylvania, member of PulseSight's Scientific Advisory Board
PST-611 combines mechanistic relevance, long-lasting efficacy, and a de-risked delivery platform positioning it as a potential major option for patients with dry AMD.— Thierry Bordet, Chief Scientific Officer of PulseSight Therapeutics
The Hearth Conversation Another angle on the story
So iron is just sitting in the eye causing damage? Why hasn't this been treated before?
It's been suspected for years by some researchers, but the evidence wasn't strong enough to justify a drug program. This new study is the first to show iron dysregulation in actual AMD patient samples and then prove in cells that transferrin can reverse the damage. That's the bridge from observation to mechanism to therapy.
And transferrin is something the body already makes?
Exactly. It's an endogenous protein—your liver produces it to regulate iron throughout your bloodstream. The insight here is that the eye's local iron balance breaks down in AMD, and you can restore it by delivering more transferrin directly to the retina.
How does PST-611 actually get the transferrin into the eye?
It's a plasmid—a small circle of DNA—that encodes the transferrin gene. They use an electro-transfection system to deliver it into the ciliary muscle, which sits behind the iris. Those muscle cells then act as a biological factory, continuously producing transferrin that diffuses to the retina. It's elegant because you don't need repeated injections.
How long does the effect last?
They're designing it to work for four to six months per treatment. That's much longer than most eye therapies, which often need monthly or quarterly dosing. But we won't know the actual duration until Phase I results come back early next year.
What's the human stakes here? Why should someone care about this beyond the science?
AMD is the leading cause of vision loss in people over 65. It's not painful, but it's relentless—you gradually lose the ability to read, recognize your grandchildren's faces, drive safely. Two hundred million people worldwide have it. For most, there's no cure, only management. A therapy that actually addresses the root cause could preserve vision for millions of people.